Fox Chase Cancer Center Study: Long Term Hormone Therapy Improves Outcome for Prostate Cancer Patients Treated with 3D Conformal Radiation Therapy
PHILADELPHIA (November 7, 2001) -- A Fox Chase Cancer Center study demonstrates that patients with locally advanced non-metastatic prostate cancer have better outcomes when treated with long term hormone therapy in addition to high dose 3-dimensional conformal radiation therapy (3DCRT). The finding will be presented by Eric M. Horwitz, MD - Chair, Radiation Oncology; Gerald E. Hanks Chair in Radiation Oncology., associate member of the Radiation Oncology Department at Fox Chase Cancer Center, Philadelphia, Pa., at the American Society for Therapeutic Radiology and Oncology Annual Meeting in San Francisco, Ca. on Wednesday, November 7 at 12:00 p.m. PT.
"The benefit of long-term adjuvant hormones combined with conventional doses of radiation has been demonstrated in the treatment of locally advanced prostate cancer in several randomized prospective studies," explained Horwitz. "There was no study looking at adding hormone therapy to high dose 3DCRT treatment."
For the study, biochemical endpoints were compared between patients with locally advanced prostate cancer treated with high dose 3DCRT with and without long-term adjuvant hormones (LTH). These patients demonstrated T1/T2a disease with Gleason score (GS) 8-10 or T2b/T3 disease with any Gleason score.
Between January 1991 and December 1999, 236 patients meeting these criteria with locally advanced non-metastatic prostate cancer were treated with high dose 3DCRT at Fox Chase Cancer Center. Sixty-five (65) patients received at least 6 months of LTH with 3DCRT, and 171 patients were treated with 3DCRT alone.
The median follow-up for all patients was 35 months, 40 months for the LTH patients and 34 months for the 3DCRT alone patients.
Eighty (80) percent (9/65) of the patients treated with 3DCRT and LTH demonstrated biochemical control at 8 years. Fifty-seven (57) percent (42/171) of the patients treated with 3DCRT alone demonstrated biochemical control at 8 years.
"Our finding demonstrates the clear advantage hormones add to even high dose 3D CRT treatment," said Horwitz. "Long-term hormones in addition to 3DCRT continues to be the standard of care for men with locally advanced non-metastatic prostate cancer."
Other authors on the study include Alexandra L. Hanlon, Ph.D. Wayne H. Pinover, D.O., and Gerald E. Hanks, M.D.
Fox Chase Cancer Center, one of the nation's first comprehensive cancer centers designated by the National Cancer Institute in 1974, conducts basic and clinical research; programs of prevention, detection and treatment of cancer; and community outreach. For more information about Fox Chase activities, visit the Center's web site at www.fccc.edu.
Fox Chase Cancer Center, part of the Temple University Health System, is one of the leading cancer research and treatment centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence four consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. For more information, call 1-888-FOX CHASE or (1-888-369-2427).
Media inquiries only, please contact Jeremy Moore at 215-728-2700.